Dawson N J, Kemball-Cook G, Barrowcliffe T W
Division of Haematology, National Institute for Biological Standards and Control, South Mimms, Herts., UK.
Haemostasis. 1989;19(3):131-7. doi: 10.1159/000215905.
We have assayed two different monoclonal-antibody-purified concentrates (A and B) and one conventional concentrate (C), against the 3rd International Standard for factor VIII concentrate, using one-stage, two-stage and chromogenic methods. One-stage assays performed with immunodepleted plasmas gave lower potencies than with haemophilic plasma for all concentrates, though the discrepancies were most marked for the two highly purified products. The absence of von Willebrand factor in one of the immunodepleted plasmas appeared to contribute towards the low potencies observed. In addition, potencies of product A were 50% higher by one-stage assays (haemophilic plasma) than by two-stage or chromogenic methods. These results indicate the need for careful evaluation of assay methodologies for assessment of factor VIII:C activity in highly purified concentrates.
我们使用一步法、两步法和发色底物法,针对第3版凝血因子VIII浓缩物国际标准品,对两种不同的单克隆抗体纯化浓缩物(A和B)以及一种传统浓缩物(C)进行了检测。用免疫去除血浆进行的一步法检测中,所有浓缩物的效价均低于用血友病血浆检测的结果,不过两种高度纯化产品的差异最为明显。其中一种免疫去除血浆中缺乏血管性血友病因子,这似乎是观察到效价较低的原因之一。此外,通过一步法检测(血友病血浆),产品A的效价比两步法或发色底物法高50%。这些结果表明,对于评估高度纯化浓缩物中凝血因子VIII:C活性的检测方法,需要进行仔细评估。